H. S. Rugo

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Sylvia Adams, P. Schmid, H. S. Rugo et al. · Annals of Oncology · 2018 · 795 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

J. O’Shaughnessy, Lee S. Schwartzberg, Michael A. Danso et al. · Journal of Clinical Oncology · 2011 · 244 citations

Medicine, Oncology, Pharmacology +16

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

H. S. Rugo, Sherene Loi, Sylvia Adams et al. · Annals of Oncology · 2019 · 115 citations · Full text

Medicine, Oncology, Breast Oncology +13

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

Leisha A. Emens, Sylvia Adams, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17